Price Jackson

Radiation Dosimetry in Lu-177-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

Price A Jackson, Michael S Hofman, Rodney J Hicks, Mark Scalzo, John Violet

Journal article  |  2020  |  Journal of Nuclear Medicine

Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally resource-intensive, requiring multiple ..

Technical Note: Rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry

Price Jackson, Lachlan McIntosh, Michael S Hofman, Grace Kong, Rodney J Hicks

Journal article  |  2020  |  Medical Physics

BACKGROUND: Dosimetry in nuclear medicine often relies on estimating pharmacokinetics based on sparse temporal data. As analysis m..

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-177-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Thang Sue-Ping, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott G Williams, Rod J Hicks, et al.

Journal article  |  2020  |  Journal of Nuclear Medicine

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation ..

Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE is Highly Efficacious Against a Somatostatin Positive Neuroendocrine Tumor Model.

Carleen Cullinane, Charmaine M Jeffery, Peter D Roselt, Ellen M van Dam, Susan Jackson, Kevin Kuan, Price Jackson, David Binns, Jessica van Zuylekom, Matthew J Harris, Rodney J Hicks, Paul S Donnelly

Journal article  |  2020  |  Journal of Nuclear Medicine

Peptide receptor radionuclide therapy using radiolabeled octreotate is an effective treatment for somatostatin receptor 2 expressi..

A future of automated image contouring with machine learning in radiation therapy.

Price Jackson, Tomas Kron, Nicholas Hardcastle

Journal article  |  2019  |  Journal of Medical Radiation Sciences

Automated image contouring is showing improvements in efficiency for a number of clinical tasks in radiotherapy. While atlas segme..

Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol

Amir Iravani, Benjamin Solomon, David A Pattison, Price Jackson, Aravind Ravi Kumar, Grace Kong, Michael S Hofman, Tim Akhurst, Rodney J Hicks

Journal article  |  2019  |  Thyroid

Background: Some patients with metastatic differentiated thyroid cancer (DTC) lack iodine avidity and are the..

Cu-64-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

Rodney J Hicks, Price Jackson, Grace Kong, Robert E Ware, Michael S Hofman, David A Pattison, Timothy A Akhurst, Elizabeth Drummond, Peter Roselt, Jason Callahan, Roger Price, Charmaine M Jeffery, Emily Hong, Wayne Noonan, Alan Herschtal, Lauren J Hicks, Amos Hedt, Matthew Harris, Brett M Paterson, Paul S Donnelly

Journal article  |  2019  |  Journal of Nuclear Medicine

Dual-Energy CT Ventilation & Perfusion Imaging as An Accessible Alternative to Nuclear Medicine Techniques

J Korte, N Bucknell, S Siva, B Woon, P Jackson, T Mulcahy, J Callahan, T Kron, N Hardcastle

Conference Proceedings  |  2019  |  MEDICAL PHYSICS

Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework

Hayley M Reynolds, Scott Williams, Price Jackson, Catherine Mitchell, Michael S Hofman, Rodney J Hicks, Declan G Murphy, Annette Haworth

Journal article  |  2019  |  BJU International

Dosimetry of Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman

Journal article  |  2019  |  Journal of Nuclear Medicine

Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Michael Hofman, John A Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Timothy J Akhurst, Jennifer Mooi, Christina Guo, Ben Tran, Price Jackson, Mark Scalzo, Peter Eu, Scott Williams, Shahneen Kaur Sandhu

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Voxel based dosimetry of Lu-177-PSMA-617 within a prospective clinical trial: Whole body tumour dosimetry and correlations with pre-therapeutic imaging and biochemical outcomes

JA Violet, P Jackson, J Ferdinandus, S Thang, S Sandhu, M Scalzo, RJ Hicks, MS Hofman

Conference Proceedings  |  2018  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy

Price Jackson, Nicholas Hardcastle, Noel Dawe, Tomas Kron, Michael S Hofman, Rodney J Hicks

Journal article  |  2018  |  Frontiers in Oncology

[Lu-177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu

Journal article  |  2018  |  The Lancet Oncology

High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial

Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks

Conference Proceedings  |  2018  |  JOURNAL OF NUCLEAR MEDICINE